He hua pūtau CAR-T whānui te RD13-02 e aro ana ki te CD7 i ahu mai i ngā kaituku hauora, ā, i hangaia mō te rongoā i te mate toto toto nui/lymphoma lymphoblastic acute pūtau-T kua hoki mai, kua ātete rānei ki te mate. Kua whakarerekētia te ira hei karo i te mate whakamate whanaunga, te mate graft-versus-host (GvHD), me te whakakorenga host-versus-graft (HvG) me te whakarei ake i te mahi ārai-pukupuku. Ka taea te whakarite i te RD13-02 i roto i te puranga kotahi mō te tini tāngata, ka tutuki ai he kaha "kua oti kē te whakarite" mō ngā tūroro e hiahia ana ki te rongoā pūtau CAR-T.
I te 7 o Noema, 2024, i panuitia e Bioheng Therapeutics ka whakaatuhia e rātou ngā raraunga haumanu Wāhanga Tuatahi hou o tana hua pūtau CAR-T whānui RD13-02, e aro ana ki te CD7 mō te maimoatanga o ngā tūroro T-ALL/LBL kua hoki whakamuri/aukati (R/R), i roto i tētahi whakaaturanga ā-waha i te Hui-ā-Tau 66 o te American Society of Hematology (ASH). Ka tū te hui mai i te 7-10 o Hakihea, 2024, i San Diego, USA.
Ngā Hua: I te 1 o Ākuhata, 2024, e 18 ngā tāngata whai mana me te R/R T-ALL/LBL i whakaurua (13 ALL, 5 LBL), me te tau toharite o te 33.5 tau (awhe, 11 ki te 67). Ko te toharite o ngā raina rongoā o mua ko te 2 (awhe, 1 ki te 5), ā, e 4 ngā tāngata i mua i te whakaurunga i te allo-HSCT. Ko te ōwehenga toharite o ngā pahūtanga BM ko te 71% (awhe: 6% ki te 90%) i roto i te 18 ngā tāngata, me te 9 (6 ALL, 3 LBL) e whakaatu ana i te whai wāhi ki waho o te medullary. Kāore i kitea he huihuinga paitini whakawhāiti horopeta (DLT) me te paitini neuro i ngā taumata horopeta katoa, kotahi anake te take o te Gr1 GvHD i puta. I taea te whakahaere i te mate tukunga cytokine (CRS) me te nuinga he ngawari (Gr1, n=10; Gr2, n=5; Gr3, n=3). I puta ngā mate urutā katoa i roto i te 13 (72%) ngā tohu (≥Gr3 i roto i te 2 [11%] ngā tohu). Nā te putanga mai o te Gr3 CRS i roto i te kotahi tohu ia tohu mai i ngā taumata DL2 me DL3, i whakatakoto ngā kairangahau i te DL1 hei horopeta whakawhānui me te arotahi nui ki te haumaru me te whai huatanga. I te wā o te whakawhānui i te horopeta, kotahi te tohu i mate i te mate pukupuku pakaru i te Rā 20 i muri i te werohanga.
I te aromatawai tuatahi mō ngā rā 28 i muri i te werohanga, 14 o te 17 o ngā tohu aromatawai i eke ki te CR/CRi. Engari i te rua o ngā marama i muri i te werohanga, e rua atu ngā tohu i eke ki te CR/CRi, me te reiti CR/CRi o te 94% (16/17). I roto i ngā tohu me te CR/CRi, 100% i eke ki te āhua kino o te mate toenga iti (MRD) mā te tātaritanga flow cytometry. Ko te Cmax toharite o ngā pūtau CAR-T i roto i te toto ā-taha he 1,863,601 kape/μg DNA ira (awhe, 275,044 ki te 3,763,587) mā te qPCR, me te roanga roa rawa atu neke atu i te 90 rā.
Whakatau: Ko te RD13-02, he hua CAR-T whānui "kua oti te hoko", i whakaatu i tētahi āhua haumaru ka taea te whakahaere me te whai huatanga kua whakarei ake i te rongoā i te R/R CD7 T-ALL/LBL. He mea nui, 100% o ngā tohu CR/CRi i eke ki te tūnga MRD-kino, e tuku ana i ngā tohu he kōwhiringa maimoatanga tere ake.
I tēnei wā, he maha atu ngā whakamātautau haumanu CAR-T i Haina, ā, kei te rapu tūroro rātou. Mō te kōrerorero mō ngā rongoā me ngā hangarau hou, ka taea e koe te whakapā atu ki te Tari Ao o te Hōhipera Oncology Rohe Tonga o Beijing.
Tau Waea：4008803716
Email：myimmnet@163.com
Ngā Tohutoro
1.https://www.bioheng.com/News_Details/26.html
2.https://ash.confex.com/ash/2024/webprogram/Paper207322.html
3.http://myimm.net/mianyizhiliao/2035.html
Wā tuku: Hakihea-03-2024